Optimum Investment Advisors Raises Holdings in Johnson & Johnson (NYSE:JNJ)

Optimum Investment Advisors increased its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 1.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 7,060 shares of the company’s stock after acquiring an additional 128 shares during the period. Optimum Investment Advisors’ holdings in Johnson & Johnson were worth $1,153,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in JNJ. Wellington Management Group LLP lifted its stake in Johnson & Johnson by 0.8% during the first quarter. Wellington Management Group LLP now owns 32,772,594 shares of the company’s stock worth $5,808,286,000 after purchasing an additional 265,330 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Johnson & Johnson by 18.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after purchasing an additional 3,912,430 shares in the last quarter. Legal & General Group Plc lifted its stake in Johnson & Johnson by 2.3% during the second quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock worth $3,344,295,000 after purchasing an additional 421,779 shares in the last quarter. FMR LLC lifted its stake in Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after purchasing an additional 3,229,032 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Johnson & Johnson by 1.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after purchasing an additional 328,297 shares in the last quarter. 67.94% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In related news, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Jennifer L. Taubert sold 76,923 shares of the firm’s stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The disclosure for this sale can be found here. Insiders sold a total of 300,750 shares of company stock worth $52,311,677 over the last 90 days. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $180.25 on Monday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The stock’s 50-day moving average is $176.05 and its two-hundred day moving average is $171.65. The firm has a market cap of $471.26 billion, a price-to-earnings ratio of 25.10, a PEG ratio of 3.45 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm had revenue of $23.79 billion for the quarter, compared to analyst estimates of $23.44 billion. During the same quarter last year, the company posted $2.60 earnings per share. The business’s revenue was up 1.9% on a year-over-year basis. Analysts predict that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson announced that its board has initiated a share buyback plan on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the company to repurchase up to 1.2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be given a $1.13 dividend. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.51%. Johnson & Johnson’s payout ratio is currently 62.95%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on JNJ. Barclays began coverage on Johnson & Johnson in a research note on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price objective on the stock. StockNews.com began coverage on Johnson & Johnson in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Raymond James reduced their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 19th. Morgan Stanley reduced their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 6th. Finally, Credit Suisse Group initiated coverage on Johnson & Johnson in a research note on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price target on the stock. Seven analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $182.42.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.